Kornimate/medical-research-clean huggingface dataset:
repetitive arm training + fes on upper extremity motor recovery in sub-acute stroke survivors

Conditions: Stroke; Arm Motor Recovery

Summary: rehabilitation restores functions and reduces disabilities due to diseases sequelae. the relationship between intensity of rehabilitation and clinical outcomes, recently emphasized, has generated a great interest for technological high-intensity interventions. however, their effects compared to traditional interventions as well the involved biological mechanisms remain uncertain. the present strategic program aims to predict the treatment efficacy in specific rehabilitation profiles, to improve the use of "targeted" therapies and the individual management of patients affected by stroke and to transfer these findings into rehabilitative strategies.

primary endpoint: fugl-meyer upper extremity (fm-ue) secondary endpoints: box and block test (bbt), modified ashworth scale (mas); motor cortex excitability (tms); electromyography analysis of muscle activation patterns during upper extremity movements; measurements of cerebral perfusion (nirs); circulating biomarkers (see figure 3 and table 1). overall assessments will be performed pre-, mid-, post-treatment and at 6-months follow-up.

Eligibility criteria:
inclusion criteria: * males and females, age 18 to 79 years * diagnosis of first, single unilateral ischemic stroke verified by brain imaging \< 8 weeks * upper limb motor function defined by an fm-ue score \> 11 and \<55 exclusion criteria: * medical conditions likely to interfere with the ability to safely complete the study protocol * impaired cognitive functioning: score less than 24 on the mini mental status examination (mmse) * severe upper-limb pain, referred as \> 7 at visual analog scale (vas) * history of seizures or epilepsy

Keywords: stroke rehabilitation arm motor recovery biological biomarkers
a study of nipocalimab or intravenous immunoglobulin (ivig) in pregnancies at risk of fetal and neonatal alloimmune thrombocytopenia (fnait)

Conditions: Thrombocytopenia, Neonatal Alloimmune

Summary: the purpose of this study is to assess the efficacy and safety of nipocalimab in reducing the risk of severe fetal and neonatal alloimmune thrombocytopenia (fnait).


Eligibility criteria:
inclusion criteria: * pregnant and an estimated gestational age from week 13 to 18 at visit 1 * has a history of greater than or equal to (\>=) 1 prior pregnancy with fnait based on medical records including: a) neonatal platelet count less than (\<) 150\*10\^9/liter with no fetal/neonatal intracranial hemorrhage (ich) or severe fetal/neonatal hemorrhage (standard-risk) or b) fetus/neonate with ich or severe hemorrhage in a fetus/neonate (high-risk) * current pregnancy with presence of maternal anti-hpa-1a and/or anti-hpa-5b alloantibody and positive fetal hpa-1a and/or hpa-5b genotype as confirmed by cell-free fetal dna in maternal blood * health status considered stable by the investigator based on physical examination, medical history, vital signs, 12-lead electrocardiogram (ecg), and clinical laboratory tests performed at screening * for maternal participant and neonate/infant, willing to forego participation in another clinical study of an investigational therapy until the last follow-up visit exclusion criteria: * currently pregnant with multiple gestations (twins or more) * history of severe preeclampsia in a previous pregnancy * history of myocardial infarction, unstable ischemic heart disease, or stroke * known allergies, hypersensitivity, or intolerance to nipocalimab or its excipients, to ivig or to prednisone * has any confirmed or suspected clinical immunodeficiency syndrome or has a family history of congenital or hereditary immunodeficiency unless confirmed absent in the participant
three dose levels of cp-690,550 monotherapy versus placebo, administered orally twice daily (bid) for 6 weeks

Conditions: Rheumatoid Arthritis

Summary: the study's objective is to compare the efficacy of 3 dose levels of oral cp-690,550 monotherapy (5 mg, 15 mg, and 30 mg twice daily \[bid\]) versus placebo administered over 6 weeks for the treatment of the signs and symptoms of subjects with active rheumatoid arthritis (ra).


Eligibility criteria:
inclusion criteria: * the subject has a history of inadequate response to at least 1, but no more than 4, of the following dmards: sulfasalazine, injectable gold, methotrexate, leflunomide, cyclosporine, or a thiopurine derivative (azathioprine or 6-mercaptopurine) exclusion criteria: * current therapy with any dmard or biologic

Keywords: oral jak inhibitor clinical trial joint diseases anti-inflammatory agents rheumatic diseases dmard antirheumatic agents autoimmune diseases immune system diseases
implication of left ventricle vortex flow guided anticoagulation therapy for preventing apical thrombus formation in patients with acute myocardial infarction: multicenter prospective randomized clinical trial; innovation study

Conditions: Apical Thrombus Formation; Acute Myocardial Infarction

Summary: implication of left ventricle vortex flow guided anticoagulation therapy for preventing apical thrombus formation in patients with acute myocardial infarction: multicenter prospective randomized clinical trial; innovation study


Eligibility criteria:
inclusion criteria: 1. patient is ≥ 30 years old 2. acute anterior wall myocardial infarction showing akinetic or dyskinetic apical wall motion abnormalities on an initial transthoracic echocardiogram 3. left ventricular ejection fraction less than 40% exclusion criteria: 1. prior history of myocardial infarction 2. chronic medication with coumadin 3. contraindication of contrast echocardiography 4. significant atrial or ventricular arrhythmia 5. valvular heart disease more than moderate degree 6. decompensated heart failure 7. very poor echo window, which cannot evaluate the presence of apical thrombus

Keywords: vortex thrombus contrast echocardiography prediction and prevention of apical thrombus formation in acute myocardial infarction patient by using vortex parameters.
fractional laser as treatment option for various pigment disorders

Conditions: Pigmentation Disorder

Summary: the purpose of this study is to determine whether the use of ablative fractional laser is effective in the treatment of becker's nevus.

becker's nevus (bn) is an uncommon pigment disorder of the epidermis characterized by increased pigmentation, a slightly elevated, verrucous surface of the affected skin and sometimes hyperpigmentation. no effective treatment is available. several laser modalities have been applied in the treatment of becker's nevus in uncontrolled studies with varying results. recently, fractional laser therapy was suggested as treatment option for becker's nevus. in fractional laser therapy, microscopic columns of skin are coagulated or ablated, leaving the surrounding tissue intact, which enhances healing of the treated skin. in this study, the efficacy and safety of ablative fractional laser therapy was assessed in the treatment of becker's nevus.

Eligibility criteria:
inclusion criteria: * becker nevus * subjects attending the outpatient department of the netherlands institute for pigment disorders * age at least 18 years * subject is willing and able to give written informed consent exclusion criteria: * use of bleaching creams during the past six weeks * history of keloid * active eczema * suspected hypersensitivity to lidocaine or triple therapy * use of isotretinoin in the past six months * high exposure of the lesion to sunlight or uv light (uva or uvb).

Keywords: becker's nevus ablative fractional laser therapy randomized controlled trial split-lesion design
consensus statements on definition, components and grading of postoperative pulmonary complications

Conditions: Postoperative Pulmonary Complications

Summary: an international team of experts is working on a project called precision to develop a clear, consistent definition of ppcs. the goals of this study are to: * define postoperative pulmonary complications in a way that makes sense for patients, families, and healthcare providers. * rank complications by severity so doctors can focus on the most serious ones first. * decide how and when to monitor patients after surgery to catch problems early.

postoperative pulmonary complications (ppcs) are associated with prolonged hospital stays, increased mortality, and significant clinical and economic burdens. despite their importance, the definition of ppcs varies across studies, leading to inconsistencies in reported incidence rates and research outcomes. existing definitions, such as the epco criteria, have been developed based on expert opinion but lack systematic consensus-building methods. to address these limitations, the step collaboration conducted a systematic review and delphi process to refine ppc classifications. however, challenges remain, including the lack of universal definitions, hierarchical ranking of complications, and representation from diverse healthcare settings. composite outcome measures improve statistical power but may obscure differences in severity and clinical significance among ppc subtypes. the precision delphi initiative aims to develop an expert consensus on defining ppcs, grading their severity, and determining standardized monitoring methods. the goal is to create a valid, reliable, and universally accepted patient-centered definition of ppcs that enhances comparability across studies and informs clinical decision-making.

Eligibility criteria:
inclusion criteria: panellists will be identified based on either of the following criteria * at least 10 years of clinical experience as a staff member in anesthesiology, surgery or intensive care medicine with involvement in care of patients with postoperative complications * author of at least three publications (observational studies or randomised controlled trials) using postoperative pulmonary complications as a primary or secondary outcome exclusion criteria - none

Keywords: postoperative pulmonary complications postoperative complications postoperative pulmonary atelectasis postoperative pulmonary care outcomes assessment delphi study
efficacy and tolerability of nicotinamide plus cream for moderate acne vulgaris in indonesia

Conditions: Acne Vulgaris

Summary: acne vulgaris (av) is a chronic inflammatory disease of the pilosebaceous unit that affects seborrheic areas such as the face, back and chest. av is characterized by blackheads, papules, pustules nodes and cysts with sequelae of hyperpigmentation and scarring. it is one of the most common skin disorders treated by dermatologists. acne vulgaris can be found at any age, although it is more frequent in teenagers and young adults. the prevalence of av in a population of 11 to 30 years old is approximately 80%. due to its involvement of the face, it is considered to be a cosmetic problem, thus bearing a psychosocial burden.


Eligibility criteria:
inclusion criteria: * moderate acne vulgaris * 12 and up to 50 years old, * agreed to become research participants and has signed the informed consent. exclusion criteria: -
study of recombinant human serum albumin/interferon alpha2b fusion protein in hepatitis b patient

Conditions: Hepatitis B Virus

Summary: the purpose of this study is to evaluate the dosages of recombinant human serum albumin/interferon alpha2b fusion protein injection on hbv subjects. the secondary purposes is to get the pk/pd data in recombinant human serum albumin/interferon alpha2b fusion protein injection on hbv subjects.

this is an open-label study that will be conducted at three sites in china to characterize the pk/pd profile, safety and tolerability of recombinant human serum albumin/interferon alpha2b fusion protein in hbv subjects. subjects will receive a single dose of recombinant human serum albumin/interferon alpha2b fusion protein or active comparator pegasys at day 0. a multipule-dose administration in hbv subjects will last 12 weeks after four weeks washout period.

Eligibility criteria:
inclusion criteria: * hbv patients who have positive hbeag or hbeab * must be healthy males or females between 18 to 60 years old * must have a body mass index (bmi) of 18 to 30 kg/m2 * hbv dna≥2000 iu/ml * alt≥1.3 uln and ≤10 uln exclusion criteria: * administrated a nucleoside analogues (acid) or interferons against hepatitis b virus drugs, immunosuppressants, immune regulator before 6 months;or any other against hepatitis b virus therapy at the same time. * participated in other clinical trials within a month. * allergic to interferon. * t-bil ≥2 uln. alb\<35g/l. pt≥4s. * positive hcv-ab,hev-ab,ebv-ab,cmv-ab,tppa,hiv-ab. * organ transplant patients, except cornea or hair transplantation. * other hepatopathy exclude nafld . * drug addiction or alcohol dependence. * malignancy(except cured cervical carcinoma in situ, bcc, squamous cell carcinoma) except liver history. * serious retinal disease. * active hemorrhagic disease or severe hematopoietic dysfunction or blood coagulation disorder. * autoimmune disease. * uncontrolled diabetes or thyroid disease or beyond grade 2 blood pressure. * wbc\<3×109/l or anc\<1.5 ×109/l or plt\<90 ×109/l or hgb\<uln. * hcc or afp\>100ng/ml. * chronic kidney disease or scr\>uln. * lactating women or pregnancy. * cardiovascular and cerebrovascular events within 6 months. * neurological or psychiatric disease or family history.
abdominal aortic aneurysm stabilization with truncal cells: controlled clinical trial with historical cohorts

Conditions: Aortic Aneurysm, Abdominal

Summary: phase iia, single-center clinical trial compared with historical cohorts to evaluate the preliminary safety and efficacy of an allogeneic adipose tissue-derived mesenchymal stem cells infusion in an aneurysmal sac for the treatment of aaa.


Eligibility criteria:
inclusion criteria: 1. subjects with aaa greater than 5 cm diameter with endovascular treatment indication, analyzed by aortic angioct. 2. subjects ≥ 18 years at the time of inclusion. 3. subjects with a good infrarenal neck for a standard device placement, neither fenestrated nor branched. 4. patients with an estimated life expectancy greater than 2 years at the time of inclusion. 5. women with childbearing capacity must have a negative pregnancy test at the time of inclusion and must agree to use highly effective contraceptive methods (diaphragms plus spermicide or male condom plus spermicide, oral contraceptive combined with a second method contraceptive implant, injectable contraceptive, permanent intrauterine device, sexual abstinence or partner with vasectomy) during their study participation. 6. the patient must be able to attend all study visits and comply with all study procedures. exclusion criteria: 1. patients with unresolved neoplasia history or hematologic disease. 2. patients with uncontrolled arterial hypertension (≥180/110) at the time of inclusion. 3. patients with severe heart failure (new york heart association \[nyha\] iv) or ejection fraction \<20%. 4. patients with malignant ventricular arrhythmias 5. patients with deep vein thrombosis the last three months 6. patient with active sepsis at the time of inclusion 7. patients with acute myocardial infarction or stroke in the previous month 8. any type of medical or psychiatric illness that, in investigator opinion, could be a reason for exclusion from the study. 9. patient with major surgery or severe craniocerebral trauma in the 3 months prior to inclusion in the study. 10. administration of any investigational drug at the time of inclusion or in the 3 months prior 11. infants or pregnant women 12. transplanted patients.
nutrition, diabetes and pulmonary tb/hiv

Conditions: Tuberculosis; HIV; Diabetes

Summary: we propose a randomised trial among pulmonary tb patients, examined and treated as part of the national tb control programme (who, 2003). the aim is to improve tb treatment outcome in high tb and hiv burden countries. the overall objective of the proposed trial is to assess the effect of nutritional support on tb treatment outcomes, and to assess the role of diabetes on risk and severity of tb, and tb treatment outcomes. the study will be conducted in mwanza tanzania. all patients will initially be examined for hiv and diabetes. a total of 500 found pulmonary tb smear-positive (ptb+) and hiv positive (hiv+) will be randomised to a daily supplement of 1 versus 6 energy-protein bars throughout treatment, both with full multi-micronutrient (mn) content. a total of 1500 found pulmonary tb smear-negative (ptb-, irrespective of hiv status) and ptb+ and hiv negative (hiv-) will be randomised to 1 daily energy-protein bar containing either low or high mn content.


Eligibility criteria:
inclusion criteria: * new sputum smear positive or negative pulmonary tb patients exclusion criteria: * pregnant, terminally ill, other serious diseases (except hiv and diabetes), non-residents

Keywords: tuberculosis hiv diabetes protein-energy micronutrients
a case control study of patients with diagnosis of malignant hyperthermia

Conditions: Malignant Hyperthermia

Summary: the purpose of the study is to develop methods to identify predictors of malignant hyperthermia.

the current study will use the combination of electronic medical records and genomic information in samples of persons who have exhibited signs of malignant hyperthermia (mh) or have family history or high risk of mh to see if risk factors can be identified. these will be compared with control samples of children who have been exposed to the same agents which could induce mh, yet showed no signs of the disorder.

Eligibility criteria:
inclusion criteria: * malignant hyperthermia cases: diagnosis of malignant hyperthermia * control cases: children who participated exclusion criteria: * not meeting the inclusion criteria stated above
comparison of patient controlled analgesia (pca) versus bolus narcotic therapy for the treatment of vaso-occlusive crisis (voc)

Conditions: Sickle Cell Disease; Vaso-occlusive Crisis

Summary: this research is being done to find out the best way to give narcotics for pain relief in adults with sickle cell disease and painful crisis. this study is a comparison of two ways of giving narcotics. the first way is what occurs now in the emergency acute care unit (eacu) where patients are given a single intravenous (iv) dose of a narcotic which is repeated by the nurse as needed to control the pain. the second way is to provide a single iv dose of narcotic and then allow the patient to push a button and receive one or more additional doses of narcotic when he/she thinks it is needed. our hypothesis is that pca will be a more effective way of controlling pain.


Eligibility criteria:
inclusion criteria: * documented sickle cell disease * signed consent in outpatient clinic or during a prior hospitalization * 18+ years of age * seen in the ed with sickle cell pain crisis - this will be based on patients chief complaint that they are in a voc. * requires iv administration of narcotics (has failed oral narcotic therapy at home) * must be 2 weeks since their last randomization on this study. exclusion criteria: * contraindication to the use of iv narcotics * hypotension with systolic blood pressure (sbp) ≤ 90 * respiratory rate ≤9 * altered mental status * patient unable to understand how to use the pca device * patient unwilling to use pca device * pulse oximeter reading of ≤ 94% on room air * patient is allergic to iv morphine \& hydromorphone \& fentanyl. * patient is allergic to oral hydromorphone \& morphine \& oxycodone * patient has been randomized on this study 3 times before
vides trial (vitamin d extra supplementation)

Conditions: Vitamin D Deficiency

Summary: the objective of the study is to compare supplementation with vitamin d at 800 iu/day to usual care for the first 28 days after birth with respect to 25 (oh) vitamin d levels and indicators of likely or plausible effects of vitamin d supplementation on the function or structure of the lung, bones, immune system, and brain in extremely premature (ep) infants who are \<28 weeks gestational age (ga) or \<1000 grams of birth weight (bw). the study results will be analyzed as intention to treat bayesian analyses (frequentist analyses will also be performed).


Eligibility criteria:
inclusion criteria: * infants born at \< 28 weeks gestational age (ga) or \<1000 grams birth weight (bw) * inborn * informed written consent in an institutional review board (irb)-approved manner exclusion criteria: * ga \>32 weeks regardless of birth weight (bw) * any major congenital anomaly * a known congenital nonbacterial infection * prenatal diagnosis of disorders that affect vitamin d absorption (e.g, cystic fibrosis) * such severe illness or immaturity that the attending neonatologist judges intensive care to be unjustified.

Keywords: premature infant vitamin d
open-label safety and tolerability study of oxymorphone for acute postoperative pain in pediatric subjects.

Conditions: Postoperative Pain

Summary: when post-operative parenteral analgesia is discontinued, oral dosing with study medication may begin once the subject has developed a moderate level of pain as defined by a 100 mm vas (pain intensity score greater than or equal to 40). this post marketing study was required by the fda. endo pharmaceuticals inc. no longer promotes opioids and no longer markets opana® er.


Eligibility criteria:
inclusion criteria: * male or female \> 12 to 17 years of age, inclusive * weigh at least 50 kg * postoperative oral opioid analgesia required for at least 24 hours or 48 hours following postoperataive parenteral analgesia * are expected to be hospitalized for the duration of the study exclusion criteria: * known allergy to, or a significant reaction to, oxymorphone or another opioid * life expectancy of \< 4 weeks * positive pregnancy test at screening

Keywords: opioid tolerant pediatric pain non malignant malignant
radiofrequency ablation plus radiotherapy for small hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma

Summary: radiofrequency ablation (rfa) and hepatic resection are main treatments for early stage hepatocellular carcinoma. many randomized controlled trials found these two treatments have similar short term overall survival. however, hepatic resection is associated with higher long-term overall survival. these results reveal that tumor recurrence rate after rfa is higher than that after hepatic resection. and minimal residual tumor may exist after rfa. radiotherapy after rfa may be effective to prevent early tumor recurrence.


Eligibility criteria:
inclusion criteria: 1. clinical diagnoses of hepatocellular carcinoma based on easl. 2. tumors, either single, \>2 and \< 5 cm in size or no more than 3 for size \< 3 cm. 3. patients must have a performance status of ecog score \< 2. 4. patients must have adequate liver reservation and adequate hemogram. * pugh-child's score \< 7. * the serum total bilirubin level are \< 2 mg/dl. * the prothrombin times are \< 3 sec above normal control. * the platelet are \> 75 x 109/l. 5. patient must have serum creatinine \< 1.5 mg/dl 6. cardiac function with nyha classification \< grade ii 7. hbsag (+) . 8. signed informed consent. exclusion criteria: 1. hccs with radiological evidence of macrovascular invasion or extrehepatic metastasis are not eligible. 2. patients with other systemic diseases which required concurrent usage of glucoticosteroid or immunosuppressant agent(s) are not eligible. 3. patients with advanced second primary malignancy are not eligible. 4. patients with pregnancy or breast-feeding are not eligible. 5. patients with severe cardiopulmonary diseases are not eligible. 6. patients with clinically significant psychiatric disorder are not eligible. 7. patients who had antineoplastic chemotherapeutic or immuno-therapeutic drugs or corticosteroids within 6 weeks of commencing the protocol are not eligible. 8. patients who had prior antitumor therapy for hcc are not eligible. 9. anti-hcv positive patients are not eligible.